On September 20, 2021 INmune Bio, Inc. (NASDAQ: INMB) (the "Company"), a clinical-stage immunology company focused on developing treatments that harness the patient’s innate immune system to fight disease, reported that Raymond J. Tesi, MD, President and CEO, is scheduled to participate in two upcoming investor conferences in September 2021 (Press release, INmune Bio, SEP 20, 2021, View Source [SID1234590129]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Oppenheimer Fall Healthcare Life Sciences & MedTech Summit
Presentation Date: Wednesday, September 22
Presentation Time: 1:15pm ET

Cantor Fitzgerald Global Healthcare Conference
Presentation Date: Wednesday, September 29
Presentation Time: 3:20pm ET
Webcast: View Source

Please contact your representative at Oppenheimer or Cantor Fitzgerald to schedule a virtual one-on-one meeting with INmune Bio during the respective conference.